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The past few years have witnessed something of a renaissance in the field of cancer immunotherapy, relating largely to the clinical
advances that have been associated with the development of monoclonal antibodies targeting the immune inhibitory co-
receptors CTLA-4 and PD-1 and to the pursuit of genetically modified antigen-redirected adoptive T-cell therapies. These
advances are based on a more substantial understanding of the factors restricting effective immune therapies that has been
derived from the study of pre-clinical models of tumour growth in immune competent mice. Just as the recognition of the
importance of positive co-stimulatory signaling has been instrumental to recent advances in the development of genetically
modified antigen-specific adoptive cellular therapies, an increasing awareness of the ability of tumours to subvert multiple
immune inhibitory pathways, effectively blunting the development or expansion of any anti-tumour immunity, is fostering the
development of novel therapies that appear active as monotherapies but may achieve their greatest impact in combinatorial
regimens. This mini-review will focus on attempts to target co-inhibitory members of the immunoglobulin superfamily.
It is generally held that key advances in the development of
effective immunotherapies will derive both from a better biological
understanding of the immunological responses occurring during
tumour induction and growth and how the critical components of
such responses fit together, and a deeper understanding of the
processes underlying malignant transformation and cancer pro-
gression. Although these two fields of cancer immunology and
basic cancer biology have often developed along divergent
pathways, the overlap is now extending. Data supporting the
validity and aiding refinement of such key concepts as immune
surveillance and immune editing have furthered our understanding
of the dynamic nature of the relationship between host and
tumour. The basic idea that the immune system is capable of
recognising and responding to cancer has been expounded for over
150 years, with early speculation that the incidence of cancer would
be much greater were it not for the ability of the immune system to
identify and eliminate nascent tumour cells. This concept later
become known as the immune surveillance hypothesis (Burnet,
1967). Direct supportive evidence, however, remained elusive for
all but virus-associated malignancies, and the idea was
controversial until 2001, when a landmark paper by Robert
Schreiber in collaboration with Lloyd Old demonstrated that
lymphocytes and the immune stimulator interferon-g cooperate to
inhibit the development of spontaneous and carcinogen-induced
tumours in mice genetically engineered to lack a functional
immune system (RAG-2 / ; Shankaran et al, 2001). They also
recognised that some tumour cells escaped detection and
eventually caused cancer and proposed that the cellular composi-
tion of such tumours, driven by the selective pressure exerted by
immune system, becomes serially less immunogenic (immunoedit-
ing), perhaps as a consequence of downregulation of the molecules
that are required for immune recognition. Experimental support
for this idea was provided by data demonstrating that tumour cells
from immunodeficient mice were more immunogenic than those
from immunocompetent mice. The central tenets of immunoedit-
ing have evolved slightly since inception but may be considered to
consist of three processes occurring either independently or
sequentially. Firstly, ‘elimination’ in which immunity functions
as an extrinsic tumour suppressor (equivalent to the original
concept of immunosurveillance); secondly, ‘equilibrium’ in which
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cancerous cells survive but are held in check by the immune system
(Koebel et al, 2007); and thirdly ‘escape’ in which tumour cell
variants with either reduced immunogenicity or the capacity to
attenuate or subvert immune responses grow into clinically
apparent cancers. These data raise a potentially formidable obstacle
to the delivery of clinically useful immunotherapies, suggesting that
by the time a cancer becomes detectable it is already beyond the
capabilities of the host immune system to eradicate it. Critically
from the therapeutic standpoint, however, it has been demon-
strated that it is possible to make these ‘edited’ cells visible to the
immune system by increasing their antigen expression or by
manipulation of intrinsic or extrinsic regulators of immunity. A
greater focus on the tumour microenvironment, and the immune
mediators therein, has been coupled to advances in our under-
standing of the regulation of immune responses in general, leading
to the development of novel therapeutic strategies. Although many
components of the microenvironment merit consideration, includ-
ing inhibitory macrophage/monocyte populations, optimisation of
antigen presentation by dendritic cell populations, vascular
activation and chemokine signatures controlling T-cell trafficking,
and signaling via tumour necrosis factor receptor family members,
we will focus on the role of members of the co-stimulatory
immunoglobulin superfamily in shaping the anti-tumour immune
response and how these might be manipulated for therapeutic gain.
In order to mitigate uncontrolled propagation of harmful
immune responses, the immune system contains a multitude of
inhibitory feedback loops. The most critical of these have been
termed immunological checkpoints and they act to regulate the
amplitude of immune responses, to provide a molecular shield
protecting against collateral tissue damage that might occur during
immune responses to infections and to maintain peripheral self-
tolerance. A number of these key checkpoints belong to the
extended CD28 family of receptors and their ligands. This family
contributes both co-stimulatory pathways (notably CD28 and
ICOS), which are central to the development of productive
immune responses, and co-inhibitory pathways (exemplified by
CTLA-4 and PD-1, Figure 1). CTLA-4 is expressed exclusively on
T cells and its ligands CD80 (B7.1) and CD86 (B7.2) restricted
largely to professional antigen-presenting cells or other immune
mediators, for example, T cells themselves. This strict compart-
mentalisation may help to regulate the powerful inductive impact
co-stimulatory signaling has on immune responses and reflects the
importance of CD28/CTLA-4 and their shared ligands in the early
activation of productive immunity. Genetic ablation of CTLA-4
results in profound lymphoproliferation, particularly of the CD4þ
T-cell compartment, culminating in widespread tissue infiltration
and death at approximately 3–4 weeks of age in CTLA-4 / mice
(Chambers et al, 1997). PD-1 has a slightly broader expression
profile, being present also on B cells and NK cells, though much of
its physiological inhibitory function has been established in the
context of T-cell responses. By contrast, its ligands (more notably
PD-L1) have a much broader tissue distribution, being expressed
on both haematopoietic cells (B, T, myeloid and dendritic cells) as
well as non-haematopoietic cells, including microvascular endothe-
lial cells and in non-lymphoid organs, including heart, lung,
pancreas, muscle and placenta. This distribution suggests that
interaction of receptors and ligands may be more important in
regulating effector T-cell responses in peripheral tissues. Indeed,
the upregulation of PD-L1 ligand in response to interferon-g
provides one possible mechanism by which peripheral tissues
might be protected from the collateral damage that could ensue
from T-cell activation in the context of infection, providing a
localised ‘molecular shield’ inhibiting activated T cells from
targeting surrounding host tissues. The phenotype of PD-1 or
PD-L1 knockout mice is less severe than that of CTLA-4-deficient
mice (Nishimura et al, 1999; Dong et al, 2004). PD-1 knockout
mice develop tissue- and strain-specific autoimmunity at approxi-
mately 9 months of age, while PD-L1 knockout mice display
virtually no phenotype unless challenged with an infection or
crossed onto an autoimmune prone background.
Subversion of either of these two inhibitory checkpoints is
therefore a powerful mechanism by which tumours could evade
host immune responses. Support for such concepts come from the
demonstration of PD-L1 expression by a variety of human
malignancies and correlation of expression levels with poorer
overall survival. Furthermore, transfection of murine tumours with
PD-L1 renders them less susceptible to lysis by cytotoxic T cells
in vitro and markedly enhances tumour growth and invasiveness
in vivo. More recent analyses demonstrate that in cases of PD-L1þ
melanoma, PD-L1 expression is upregulated locally within the
tumour microenvironment in areas of greatest T-cell infiltration
(Taube et al, 2012). More specifically, PD-L1þ melanoma cells
were almost always localised immediately adjacent to tumour-
infiltrating lymphocytes (TILs), while tumours with minimal TIL
infiltration were less likely to express PD-L1. Interferon-g was
detected at the interface of PD-L1þ tumours and TILs, whereas
none was found in PD-L1 tumours, suggesting that TILs may
actually trigger their own inhibition by secreting cytokines that
drive tumour PD-L1 expression, a form of adaptive resistance
mediating immune escape. In other tumours, PD-L1 expression
appears to be driven by constitutively active oncogenic signaling
pathways (Parsa et al, 2007).


















Figure 1. Compartmentalisation of co-inhibitory checkpoints.
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More direct evidence for the potential therapeutic impact of
targeting these pathways came from studies in preclinical murine
tumour models demonstrating enhanced anti-tumour immunity
after antibody-mediated blockade of CTLA-4, PD-1 or PD-L1.
These studies informed the development of similar antibodies for
use in humans, and these developments form the focus of majority
of this review. The precise mechanisms underpinning the
enhanced anti-tumour immunity demonstrated with these anti-
bodies remain somewhat controversial. In addition to their direct
cell-intrinsic function in dampening effector T-cell, responses, both
CTLA-4 and PD-1 are highly expressed on regulatory T cells.
These molecules may have direct immune inhibitory roles when
expressed in trans, and engagement of the receptors on regulatory
T cells appears critical for maximal anti-tumour activity by anti-
CTLA-4 antibodies (Peggs et al, 2009b). Further dissection of the
precise mechanism(s) of activity should inform the development of
more effective therapeutics.
CTLA-4 AND THE EVOLUTION OF THE CHECKPOINT
BLOCKADE PARADIGM
CTLA-4 is the archetypal immune regulatory checkpoint.
Although the predominant mechanism by which it exerts this
activity remains unclear, and in all likelihood involves multiple
overlapping mechanisms, functionally it appears primarily to
counteract the costimulatory activity of CD28, with which it shares
its two ligands (CD80 and CD86). Its major physiological role is in
the initial activation stages of both naive and memory T cells.
CTLA-4 has a much higher overall affinity for both ligands and can
therefore out-compete CD28 for binding when ligand densities are
limiting. This ability is facilitated by its capacity to form
extended lattice-like networks with its B7 ligands, in contrast to
the likely monovalent interaction between CD28 and the
ligands. Thus CTLA-4 physically excludes CD28 from the
immunological synapse. Furthermore, it has also been proposed
to actively deliver inhibitory signals to the T cell, may influence
T-cell motility (Schneider et al, 2006) and may capture and strip its
ligands from antigen-presenting cells by trans-endocytosis
(Qureshi et al, 2011). In addition, its engagement with B7 ligands
appears to deliver inhibitory signals into the ligand-expressing
cells, and it also has suppressive activity in trans when expressed
on either regulatory or effector T cells (Wing et al, 2008; Corse and
Allison, 2012).
Early evidence for its potential as a target for enhancing anti-
tumour immunity came from murine models (Leach et al, 1996),
followed shortly thereafter by clinical evaluation of fully human
anti-CTLA-4 antibodies. Objective responses as defined by
Response Evaluation Criteria in Solid Tumours (RECIST) were
documented in 10–15% of patients, though immune-related
adverse events (IRAEs) involving a variety of tissues, including
the gastrointestinal tract, were documented in 25–30% of cases
treated at the higher doses (reviewed in Peggs et al, 2009a),
highlighting the relatively narrow therapeutic index. Clinical
responses appeared to correlate with the development of IRAEs,
though this correlation was not absolute in either direction
(Downey et al, 2007). Further development focused on defining the
most appropriate dose and scheduling, as well as on methods to
more aggressively manage IRAEs, which included budesonide and
anti-TNFa agents, culminating in two successful phase III studies
with the fully human anti-CTLA-4 monoclonal antibody
ipilimumab.
The first of these trials documented outcomes in 676 patients
with previously treated advanced melanoma (Hodi et al, 2010).
Patients were randomised to be treated either with a peptide
vaccine against the melanosomal gp100 antigen, ipilimumab or a
combination of the peptide vaccine and ipilimumab. The most
noteworthy outcome was a prolongation in overall survival in those
treated with ipilimumab, either alone or in combination with
peptide vaccination, compared with those receiving peptide vaccine
monotherapy. The median survival for the ipilimumab mono-
therapy group was 10.1 months compared with 6.4 months for the
gp100 vaccine monotherapy group (Po0.001). The combination
arm showed a similar outcome to ipilimumab alone (10.0 months).
Furthermore, 23.5% of patients in the ipilimumab group were alive
at 2 years compared with 21.6% in the combination therapy group
and only 13.7% in the gp100 group. Progression-free survival did
not differ significantly between the groups. The original primary
end point of best overall response rate was 10.9% in the
ipilimumab monotherapy group, although the ‘disease control
rate’ (including those with stable disease over a 12-week period)
was 28.5%. Of those obtaining an objective response, the response
was maintained for at least 2 years in 13 out of 38 (34%).
Approximately 15% of patients treated with ipilimumab experi-
enced grade 3–4 adverse events, and most were immune related, in
keeping with the earlier phase II studies. In seven patients, these
were causally associated with mortality. A significant number of
those surviving 2 years had ongoing IRAEs (12 vitiligo, 4 diarrhoea
or colitis and 8 endocrine requiring hormone replacement, e.g.,
hypopituitarism).
The results represented the first positive randomised clinical
trial ever reported in patients with metastatic melanoma in terms
of overall survival and the first showing a beneficial effect of a
melanoma treatment in the second-line setting. Both of the other
US FDA-approved drugs used in melanoma (dacarbazine and
IL-2) at that time were approved without phase III clinical trial
data. This trial also drew attention to the fact that immune-based
therapies work in an entirely different way to most anti-cancer
drugs that we have become accustomed to. The mechanisms
underlying the anti-tumour activity of immunostimulatory thera-
pies are indirect, relying on the activation of tumour-reactive
immune effector cells, and contrasting with the direct activity of
most conventional chemotherapeutics. The kinetics of clinical
responses may therefore differ significantly, potentially taking
longer to become manifest. Enhancing immunity may either
deliver delayed responses, or potentially hold the tumour in a state
of ‘clinical equilibrium’, delivering prolonged survival in the
absence of objective response. Judging these therapies primarily by
RECIST may therefore be inappropriate. Efforts to develop
alternative immune-related response criteria (irRC) remain some-
what controversial, but further prospective validation alongside
RECIST criteria, including evaluation in non immune-based
therapy trials should help to establish their worth (Wolchok
et al, 2009; Ribas et al, 2009; Hoos et al, 2010). One novel aspect of
the irRC is the measurement of overall tumour burden as a metric
of disease progression, compared with the baseline lesion
measurements taken with WHO and RECIST. Although this
may make good theoretical and clinical sense, it will make the
process of routine reporting of imaging studies significantly more
arduous. According to irRC, new lesions do not constitute disease
progression if net tumour burden (including new lesions) is stable
or decreases. The irRC also permit disease progression before
response and introduce the concept of confirmation of progression
at a subsequent timepoint after first detection. This accounts for
the period required for activated T cells to infiltrate the tumour,
which may cause initial increase in tumour volume but can
subsequently translate into tumour shrinkage. The irRC also
classify durable stable disease as clinical activity.
Despite the fact that the results indicated that therapeutic
benefit may be confined to a minority, and that its duration may be
modest in many of these, a small number did sustain remarkably
prolonged responses. The difference in overall survival at 2 years in
the monotherapy groups (23.5 vs 13.7%) appeared encouraging
and, while patient numbers with longer follow-up were small,
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overall survival at 4 years appeared similar in the ipilimumab
group (approximately 20%). Much effort is now being directed
at identifying biomarkers that correlate with response/outcome
to allow appropriate targeting of treatment to those likely
to gain most benefit, both to avoid exposure to potentially
harmful side effects in those unlikely to gain benefit and to
manage the financial cost associated with therapy. Such
insights might also allow development of strategies to enhance
activity in those who are unlikely to profit from ipilimumab
monotherapy.
One possible avenue for investigation in this regard is the
tumour microenvironment before therapy. A subset of patients
with melanoma display an inflamed tumour microenvironment
associated with more effective recruitment of CD8þ effector
T cells. It is tempting to speculate that the patients gaining clinical
benefit from ipilimumab are among those who have an ongoing
immune interaction between the tumour and the host immune
system, in a similar way as can be predicted for those responding to
anti-PD-1 or anti-PD-L1. Such considerations are also of
importance to contextualise these data with respect to the results
of adoptive T-cell therapies in melanoma. These have been
dramatic in many cases with response rates of up to 50%
(Dudley et al, 2008). However, successful isolation and
expansion of tumour-reactive T cells in the early studies was
possible in only approximately 30% of cases, and these are
probably over-represented by those with this more ‘inflamed’
phenotype. Response in 50% of these cases thus translates to a
response in only 15% of the overall patient population with
melanoma. These considerations raise a number of important
questions. Are these the same patients who would be responsive to
ipilimumab? If so, will a generic off-the-shelf product be more
widely applied than a patient-specific T-cell product? Although
FDA approval of the first patient-specific cellular therapeutic,
Sipuleucel-T, for advanced hormone-refractory prostate cancer has
shown that delivery models for such therapeutics can be
established, the expense and practical challenges remain
formidable. Furthermore, will this mean that combination of
these approaches (i.e., cellular therapy and costimulatory blockade)
is unlikely to significantly increase response rates? Further
exploration is clearly warranted.
Many other possible combinatorial strategies are already being
investigated in preclinical models or in the clinic. As CTLA-4 and
PD-1 signal through completely different mechanisms (Parry et al,
2005) and have distinct roles in regulating T-cell responses,
blockade could give additive or synergistic activity. Conversely, if
tumour CD8 infiltration is a strong biomarker for response with
both agents, benefits might be more modest but toxicities
compounded. A current prospective trial should answer such
questions. Other combinations with strong theoretical and
preclinical support include combinations with anti-cancer cellular
or DNA vaccines, and combinations with small-molecule inhibi-
tors (notable given the successful development of mutant BRAF
and MEK inhibitors). Combination with other conventional
therapies is also being investigated. The second important
randomised phase III study (placebo-controlled) of ipilimumab
was in combination with dacarbazine in patients with previously
untreated metastatic melanoma (Robert et al, 2011). In this trial,
502 patients were randomly assigned to receive dacarbazine with or
without ipilimumab at a somewhat higher dose. Therapy was also
more prolonged in this study compared with the earlier phase III
study. Overall survival was significantly longer in the group
receiving ipilimumab plus dacarbazine than in the group receiving
dacarbazine plus placebo (11.2 months vs 9.1 months), with higher
survival rates in the ipilimumab–dacarbazine group at 1 year
(47.3% vs 36.3%), 2 years (28.5% vs 17.9%) and 3 years (20.8% vs
12.2%). Grade 3–4 adverse events occurred in 56.3% of patients
treated with ipilimumab plus dacarbazine, as compared with 27.5%
treated with dacarbazine and placebo (Po0.001). No drug-related
deaths occurred in the ipilimumab–dacarbazine group. The results
therefore mirror those of the study in more advanced disease,
establishing a role for ipilimumab in treatment-naive patients.
Once again, the benefits were relatively modest in terms of
prolongation of median overall survival, but a minority of patients
achieved what appeared to be more durable responses. Arguably,
confirmation of durability of responses in this group will ultimately
offer the best insights into the true impact of ipilimumab in
patients with melanoma.
PD-1/PD-L1: DENTING THE MOLECULAR SHIELD
In contrast to CTLA-4, the major role of PD-1 is thought to be the
limitation of activity of T cells in peripheral tissues at the time of
an inflammatory response to infection and to limit autoimmunity.
Furthermore, chronic antigen exposure can lead to persistently
high levels of PD-1 expression, which appears to induce a state of
‘exhaustion’ or anergy of antigen-specific T-cells, but which can be,
at least partially, reversed by PD-1 blockade (Barber et al, 2006).
The finding that PD-1 is expressed by a large proportion of TILs
(Ahmadzadeh et al, 2009) and that PD-L1 is upregulated in a
number of cancers where its expression levels often correlate with
adverse outcomes, make it an attractive target for therapeutic
manipulation (Dong et al, 2002). Equally, the less severe phenotype
of knockout mice coupled with its lesser role in the early stages of
T-cell activation raises the possibility that IRAEs might be less
frequent or less severe and more likely confined to sites with
‘inflammatory’ signatures.
The early clinical experience of large phase I studies exploring
the use of anti-PD-1 or anti-PD-L1 monoclonal antibodies has
received considerable attention. The anti-PD-1 study detailed
outcomes in 296 patients with previously treated advanced cancers,
including melanoma, renal cell cancer, non-small-cell lung cancer
(NSCLC), castration-resistant prostate cancer and colorectal cancer
(Topalian et al, 2012). Patients received anti-PD-1 antibody
intravenously every 2 weeks in escalating dose cohorts, with
treatment duration up to 12 cycles. Encouraging responses were
documented in melanoma (28%), renal cell carcinoma (27%) and,
perhaps more unexpectedly, NSCLC (18%). No objective responses
were observed in the relatively small cohorts with prostate or colon
cancer. As with ipilimumab, responses appeared durable in a
number of cases (lasting over 12 months in 20 patients at the latest
follow-up). A subset of tumours were analysed for PD-L1
expression. In keeping with the proposed mechanism of action,
none of those with PD-L1-negative tumours (n¼ 17, including 9
with colorectal or prostate cancer) achieved an objective response,
compared with 9 out of 25 (36%) with PD-L1-positive tumours.
Adverse events consistent with immune-mediated causes
were observed in 41% of patients. Grade 3–4 immune-related
events occurred in only 6%, although fatal pneumonitis was seen in
three cases.
As this was a phase 1 study with multiple escalation cohorts, it is
difficult to be certain of the overall response rates, which could be
underestimated at lower doses. Nevertheless, the response rates in
melanoma looked impressive in relation to the early- and late-
phase results with CTLA-4 blockade. The responses in NSCLC,
though less frequent, are in some ways more surprising and
impressive. Objective responses were noted in 14 out of 76 (18%)
‘evaluable’ patients, and 13 out of 58 (22%) treated at dose levels of
3.0–10.0mg kg 1 (although it is unclear why 46 out of 122 of such
patients were considered non-evaluable). Eight out of 14 such
responses were documented to last X24 weeks. These results
require confirmation but point to a valuable therapeutic advance in
this difficult patient group.
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In terms of the proposed mechanism of action, the data
on responsiveness and PD-L1 expression are clearly provocative.
As 98% of PD-L1-positive tumours were associated with TILs
compared with only 28% of PD-L1-negative tumours, the majority
of human melanoma lesions fall into one of the three distinct
categories: those that are PD-L1þ and TILþ , which will likely
contain the vast majority of cases responsive to PD-1 (or PD-L1)
blockade; those that are PD-L1 and TILþ , which are unlikely to
respond to PD-L1 (and probably PD-1) blockade, but in which
other co-inhibitory pathways may be more relevant and potential
targets for manipulation (e.g., CTLA-4); and those that are PD-
L1 and TIL , which are perhaps unlikely to respond to
manipulation of co-inhibitory circuits. Although such analysis
may provide good biomarkers to allow targeting of therapies to
appropriate patient groups and to improve apparent response
rates, it is important to remain aware that patients with
TILþ tumours and favourable effector/regulatory ratios tend to
have better prognoses in any case, presumably reflective of the
impact of ongoing immune surveillance on tumour outgrowth. It
seems likely that the PD-L1 and TIL subgroup will present
the greatest therapeutic challenge in terms of manipulation of
immune inhibitory checkpoints. A further layer of complexity
is added by consideration of possible intratumoural hetero-
geneity in PD-L1 expression and TIL infiltration, which
may require evaluation with multiple biopsies from the same
individual.
With regards to toxicity, it is notable that the overall incidence
of adverse events with probable immune aetiology was not much
different in the anti-PD-1 study than the ipilimumab studies but
that the severity did appear more modest in the majority.
Interpretation is, however, confounded by the propagation of an
increased awareness of the potential for such toxicity issues and
more aggressive intervention with immune suppressants, for
example, glucocorticoids. The cases of fatal pneumonitis are clearly
of some concern, potentially restricting application of anti-PD-1 in
both the adjuvant and the neo-adjuvant settings. In this regard, it is
interesting to note that the lung is infiltrated by relatively high
levels of PD-L1-expressing antigen-presenting cells and that this
may have relevance with respect to this organ-specific toxicity.
Nevertheless, this may also be of relevance to the responses
demonstrated for both squamous and non-squamous NSCLCs. It is
clear that future combinatorial approaches evaluating agents
targeting multiple checkpoints, for example, anti-PD-1 and anti-
CTLA-4, will need very careful titration of both agents to avoid
additive or multiplicative toxicities.
A parallel phase I study investigated the use of anti-PD-L1 in a
similar patient cohort (Brahmer et al, 2012). Although response
rates looked superficially less compelling (melanoma 17%, renal
cell carcinoma 12%, NSCLC 10%), the current data cannot answer
the question as to which approach is preferable. Pre-clinical studies
have generally indicated a greater impact of PD-L1 blockade, and
specific antibody properties or dosing issues may be relevant to the
phase I clinical studies given the widespread distribution of PD-L1.
Blockade of receptor or ligand would not necessarily be expected to
be equivalent because of the complexity of the PD-1 receptor/
ligand axis. PD-L1 binds to CD80 (B7.1) with an affinity greater
than CD28 (Butte et al, 2007). Thus an anti-PD1 antibody would
block PD-1 from interacting with PD-L1 and PD-L2 but not the
interaction with PD-L1 and CD80 (potentially sequestering CD80
from exerting a co-stimulatory signal through CD28, as well as
mediating direct inhibitory signals). By contrast, an anti-PD-L1
antibody would block the interaction between PD-L1 and CD80 as
well as between PD-L1 and PD-1 but would not block the
interaction between PD-1 and PD-L2. The ability of the ligands to
back-signal into the cell expressing them (in many cases delivering
inhibitory signals) adds a further level of complexity when
considering blocking antibodies. Finally, the ability of such
antibodies to mediate agonistic signalling is also relatively poorly
understood.
CONCLUSIONS
Recent years have provided ample evidence that manipulation of
the co-inhibitory pathways that restrict anti-tumour immunity can
remove the immunological brakes that impede the induction of
clinically meaningful anti-tumour responses even when adminis-
tered as monotherapies. The next few years should see the larger
confirmatory phase 3 studies of anti-PD-1 in a number of
malignancies (likely melanoma, renal cell carcinoma and NSCLC).
These will give a better indication of the toxicity profile, which, on
first impression, appears favourable compared with that of anti-
CTLA-4 antibodies. Correlation with TIL and PD-L1 status will
also provide invaluable insights into appropriate targeting of such
therapies. We will also see the results of early combinatorial
studies, including those of conventional therapies with anti-PD-1,
and of anti-PD-1 with other immunotherapies, notably anti-
CTLA-4. Furthermore, it is noteworthy that the extended
immunoglobulin superfamily includes other apparently inhibitory
ligands for which the receptors are yet to be defined, that is, B7-H3
and B7-H4 (Zang et al, 2003; Yi and Chen, 2009; Zang et al, 2010).
These offer further possible therapeutic targets, particularly as their
expression profiles are non-overlapping with PD-L1 in some
malignancies. Finally, other inhibitory receptors, including Tim3
and LAG-3, can be upregulated on TILs establishing further
combinatorial opportunities (Sakuishi et al, 2010; Goldberg and
Drake, 2011; Woo et al, 2012). Although the overall winners in
terms of the best target(s) among these multiple possibilities will
require careful clinical evaluation, supported by dissection of
mechanism, it is perhaps more pertinent to reflect that the true
winners are likely to be the patients. Discussion will no doubt focus
more on cost implications over coming years, but this is welcome
progress. We can now move on from discussions more heavily
centred on whether immunotherapies based on enhancing pre-
existing patient anti-tumour immunity will ever have a role in the
treatment of cancer to how these will be best integrated into patient
treatment pathways.
REFERENCES
Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME,
White DE, Rosenberg SA (2009) Tumor antigen-specific CD8 T cells
infiltrating the tumor express high levels of PD-1 and are functionally
impaired. Blood 114: 1537–1544.
Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman
GJ, Ahmed R (2006) Restoring function in exhausted CD8 T cells during
chronic viral infection. Nature 439: 682–687.
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG,
Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R,
Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker
SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012)
Safety and activity of anti-PD-L1 antibody in patients with advanced
cancer. N Engl J Med 366: 2455–2465.
Burnet FM (1967) Immunological aspects of malignant disease. Lancet 1:
1171–1174.
Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1
costimulatory molecule to inhibit T cell responses. Immunity 27: 111–122.
Chambers CA, Sullivan TJ, Allison JP (1997) Lymphoproliferation in CTLA-
4-deficient mice is mediated by costimulation-dependent activation of
CD4þ T cells. Immunity 7: 885–895.
Corse E, Allison JP (2012) Cutting edge: CTLA-4 on effector T cells inhibits in
trans. J Immunol 189: 1123–1127.
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB,
Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002)
BRITISH JOURNAL OF CANCER Immune checkpoint manipulation in cancer therapy
1564 www.bjcancer.com |DOI:10.1038/bjc.2013.117
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential
mechanism of immune evasion. Nat Med 8: 793–800.
Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L (2004) B7-H1
determines accumulation and deletion of intrahepatic CD8(þ ) T
lymphocytes. Immunity 20: 327–336.
Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula
US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE,
Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical
response in patients with metastatic melanoma treated by CTL-associated
antigen-4 blockade. Clin Cancer Res 13: 6681–6688.
Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins
PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian
A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE,
Rosenberg SA (2008) Adoptive cell therapy for patients with metastatic
melanoma: evaluation of intensive myeloablative chemoradiation
preparative regimens. J Clin Oncol 26: 5233–5239.
Goldberg MV, Drake CG (2011) LAG-3 in cancer immunotherapy. Curr Top
Microbiol Immunol 344: 269–278.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB,
Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den
Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D,
Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD,
Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010)
Improved survival with ipilimumab in patients with metastatic melanoma.
N Engl J Med 363: 711–723.
Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A,
Humphrey R, Blumenstein B, Old L, Wolchok J (2010) Improved
endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:
1388–1397.
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ,
Schreiber RD (2007) Adaptive immunity maintains occult cancer in an
equilibrium state. Nature 450: 903–907.
Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor
immunity by CTLA-4 blockade. Science 271: 1734–1736.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999)
Development of lupus-like autoimmune diseases by disruption of the
PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity
11: 141–151.
Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I,
Kobayashi SV, Linsley PS, Thompson CB, Riley JL (2005) CTLA-4 and
PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell
Biol 25: 9543–9553.
Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE,
Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and
immunoresistance in glioma. Nat Med 13: 84–88.
Peggs KS, Quezada SA, Allison JP (2009a) Cancer immunotherapy:
co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol
157: 9–19.
Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP (2009b)
Blockade of CTLA-4 on both effector and regulatory T cell compartments
contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp
Med 206: 1717–1725.
Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM,
Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G,
Walker LS, Sansom DM (2011) Trans-endocytosis of CD80 and CD86: a
molecular basis for the cell-extrinsic function of CTLA-4. Science 332:
600–603.
Ribas A, Chmielowski B, Glaspy JA (2009) Do we need a different set of
response assessment criteria for tumor immunotherapy? Clin Cancer Res
15: 7116–7118.
Robert C, Thomas L, Bondarenko I, O’Day S, JW MD, Garbe C, Lebbe C,
Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M,
Hauschild A, Miller Jr. WH, Gascon P, Lotem M, Harmankaya K, Ibrahim
R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011)
Ipilimumab plus dacarbazine for previously untreated metastatic
melanoma. N Engl J Med 364: 2517–2526.
Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC
(2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion
and restore anti-tumor immunity. J Exp Med 207: 2187–2194.
Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, Wei B,
Hogg N, Garside P, Rudd CE (2006) Reversal of the TCR stop signal by
CTLA-4. Science 313: 1972–1975.
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber
RD (2001) IFNgamma and lymphocytes prevent primary tumour
development and shape tumour immunogenicity. Nature 410: 1107–1111.
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S,
Klein AP, Pardoll DM, Topalian SL, Chen L (2012) Colocalization of
inflammatory response with B7-h1 expression in human melanocytic
lesions supports an adaptive resistance mechanism of immune escape. Sci
Transl Med 4: 127ra37.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF,
Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR,
Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH,
Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M,
Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M
(2012) Safety, activity, and immune correlates of anti-PD-1 antibody in
cancer. N Engl J Med 366: 2443–2454.
Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z,
Nomura T, Sakaguchi S (2008) CTLA-4 control over Foxp3þ regulatory
T cell function. Science 322: 271–275.
Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder
M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for
the evaluation of immune therapy activity in solid tumors: immune-
related response criteria. Clin Cancer Res 15: 7412–7420.
Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini
ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto
G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ,
Drake CG, Vignali DA (2012) Immune inhibitory molecules LAG-3 and
PD-1 synergistically regulate T-cell function to promote tumoral immune
escape. Cancer Res 72: 917–927.
Yi KH, Chen L (2009) Fine tuning the immune response through B7-H3 and
B7-H4. Immunol Rev 229: 145–151.
Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP (2003) B7x: a widely
expressed B7 family member that inhibits T cell activation. Proc Natl Acad
Sci USA 100: 10388–10392.
Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT,
Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J, Allison JP (2010) Tumor
associated endothelial expression of B7-H3 predicts survival in ovarian
carcinomas. Mod Pathol 23: 1104–1112.
This work is licensed under the Creative Commons
Attribution-NonCommercial-Share Alike 3.0 Unported
License. To view a copy of this license, visit http://creativecommons.
org/licenses/by-nc-sa/3.0/
Immune checkpoint manipulation in cancer therapy BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.117 1565
